Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery Occlusion | Zendy

Celia S. Chen | Zendy; Andrew W. Lee | Zendy; Bruce Campbell | Zendy; Tien Lee | Zendy; Mark Paine | Zendy; Clare L. Fraser | Zendy; John Grigg | Zendy; Romesh Markus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery Occlusion

Author(s) -

Celia S. Chen,

Andrew W. Lee,

Bruce Campbell,

Tien Lee,

Mark Paine,

Clare L. Fraser,

John Grigg,

Romesh Markus

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.613653

Subject(s) - medicine , central retinal artery occlusion , visual acuity , tissue plasminogen activator , bolus (digestion) , anesthesia , placebo , central retinal vein occlusion , thrombolysis , occlusion , fibrinolytic agent , stroke (engine) , t plasminogen activator , surgery , myocardial infarction , mechanical engineering , macular edema , alternative medicine , pathology , engineering

Central retinal artery occlusion is caused by a platelet-fibrin thrombus or embolic occlusion and is a stroke of the eye. Observational studies suggest that thrombolytics may restore ocular perfusion and visual function. We hypothesized that intravenous tissue-type plasminogen activator (tPA) administered within 24 hours of symptom onset might restore ocular perfusion and visual function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research